Personalized Healthcare in Autoimmune Diseases - Genomic Biomarkers for Pharmaceutical Development - page 66

References
[1] Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol
2003;3(2):133-46.
[2] Morrison PJ, Ballantyne SJ, Kullberg MC. Interleukin-23 and T helper 17-type responses in intestinal inlam-
mation: from cytokines to T-cell plasticity. Immunology 2011;133(4):397-408.
[3] Kleinschek MA, Muller U, Schutze N, et al. Administration of IL-23 engages innate and adaptive immune
mechanisms during fungal infection. Int Immunol 2010;22(2):81-90.
[4] Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial
role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999;162(12):7480-91.
[5] Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin
of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125-30.
[6] Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and eficacy of ABT-874, a fully
human interleukin 12 / 23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoria-
sis: results of a randomized, placebo-controlled, Phase II trial. Arch Dermatol 2008;144(2):200-7.
[7] Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Eficacy and safety of briakinumab
vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol
2011;165(3):652-60.
[8] Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Eficacy and safety results from a Phase III, ran-
domized controlled trial comparing the safety and eficacy of briakinumab with etanercept and placebo in
patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165(3):661-8.
[9] Gordon K, Langley R, Gu Y, et al. Efficacy and safety results from a phase III, randomized controlled trial
comparing two ABT-874 dosing regimens to placebo in patients with moderate to severe psoriasis. Poster pre-
sented at Nineteenth EADV Congress. 2010.
[10] Reich K, Langley R, Papp K, et al. Efficacy and safety of ABT-874 versus methotrexate in patients with moder-
ate to severe psoriasis. Poster presented at Nineteenth EADV Congress. 2010.
[11] Grifiths CE, Girolomoni G. Does p40-targeted therapy represent a signiicant evolution in the management of
plaque psoriasis? J Eur Acad Dermatol Venereol 2012;26(Suppl. 5):2-8.
[12] Leonardi CL, Kimball AB, Papp KA, et al. Eficacy and safety of ustekinumab, a human interleukin-12 / 23
monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-
controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-74.
[13] Papp KA, Langley RG, Lebwohl M, et al. Eficacy and safety of ustekinumab, a human interleukin-12 / 23 mon-
oclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-con-
trolled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84.
[14] Grifiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-
severe psoriasis. N Engl J Med 2010;362(2):118-28.
[15] Gottlieb AB, Cooper KD, McCormick TS, et al. A Phase I, double-blind, placebo-controlled study evaluat-
ing single subcutaneous administrations of a human interleukin-12 / 23 monoclonal antibody in subjects with
plaque psoriasis. Curr Med Res Opin 2007;23(5):1081-92.
[16] Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines,
chemokines, and IL-12 / IL-23 in psoriasis. J Immunol 2006;177(7):4917-26.
[17] Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical
response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123(6):1037-44.
[18] Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12 / 23 monoclonal antibody for the treatment
of psoriasis. N Engl J Med 2007;356(6):580-92.
[19] González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev
Immunol 2012;12(2):125-35. http://dx.doi.org/10.1038 / nri3133 .
[20] Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat
Immunol 2005;6(7):722-9.
[21] Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther
2010;12(Suppl. 1):S5. http://dx.doi.org/10.1186 / ar2886 .
[22] Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat
Immunol 2005;6(7):722-9.